Since refractory celiac disease (RCD) may cause severe complications and is associated with a poor prognosis in a portion of patients, early diagnosis and treatment is of importance. Current diagnostics include complex PCR-based molecular pathology and FACS techniques in order to differentiate type I and type II RCD, the latter being associated with the development of an enteropathy-associated T cell lymphoma (EATL). Recently established treatment options also include high-dose chemotherapeutic regimens for RCD type II which have significantly improved survival. However, treatment strategies are highly individual targeting also complications of malabsorption and should be started in the RCD phase of the disease. Therefore, adequate diagnostics are pivotal for patient outcome.
- Klíčová slova
- refrakterní celiakie, RCD typu I, RCD typu II, protilátka infliximab TNF-a, tacrolimusexist, fludarabin, protilátky interleukinu - 15,
- MeSH
- atrofie MeSH
- azathioprin aplikace a dávkování farmakologie terapeutické užití MeSH
- bezlepková dieta * využití MeSH
- budesonid aplikace a dávkování farmakologie terapeutické užití MeSH
- časná diagnóza * MeSH
- časná lékařská intervence MeSH
- celiakie * diagnóza farmakoterapie komplikace patofyziologie prevence a kontrola MeSH
- diferenciální diagnóza MeSH
- histologie MeSH
- imunohistochemie metody využití MeSH
- imunosupresivní léčba * využití MeSH
- kladribin MeSH
- lidé MeSH
- melfalan aplikace a dávkování farmakologie terapeutické užití MeSH
- mesalamin terapeutické užití MeSH
- prognóza MeSH
- sérologie metody MeSH
- thioguanin terapeutické užití MeSH
- Check Tag
- lidé MeSH
